NuCana plc
- Nasdaq
- NCNA
- CIK
- 1709626
- Industry
- Pharmaceutical Preparations
- Based in
- United Kingdom
- Incorporated in
- United Kingdom
- Fiscal year ends
- December 31
- SEC filer category
- Non-accelerated filer
- Formerly
- NuCana BioMed Ltd
Key figures
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating income | −£20.1M | −£22.8M | −£32.8M | −£39.1M | −£47.9M |
| Net income | −£29.4M | −£19.0M | −£27.6M | −£32.0M | −£40.5M |
| Diluted EPS | £0.00 | −£0.26 | −£0.53 | −£0.61 | −£0.78 |
| Cash from operations | −£7.47M | −£19.1M | −£26.4M | −£23.2M | −£23.8M |
| Total assets | £29.8M | £14.8M | £27.8M | £58.3M | £77.5M |
| Shareholders’ equity | £24.3M | £5.95M | £14.9M | £38.5M | £65.5M |
From the company’s annual reports to the SEC, in GBP. Each year links to its report.
Financials 9
- 20-F Annual report (foreign issuer) for period ending Dec 31, 2025
- 20-F Annual report (foreign issuer) for period ending Dec 31, 2024
- 20-F Annual report (foreign issuer) for period ending Dec 31, 2023
- 20-F Annual report (foreign issuer) for period ending Dec 31, 2022
- 20-F Annual report (foreign issuer) for period ending Dec 31, 2021
- 20-F Annual report (foreign issuer) for period ending Dec 31, 2020
- 20-F Annual report (foreign issuer) for period ending Dec 31, 2019
- 20-F Annual report (foreign issuer) for period ending Dec 31, 2018
- 20-F Annual report (foreign issuer) for period ending Dec 31, 2017
News 139
- 6-K Current report (foreign issuer)
- 6-K Current report (foreign issuer)
- 6-K Current report (foreign issuer)
- 6-K Current report (foreign issuer)
- 6-K Current report (foreign issuer)
- 6-K Current report (foreign issuer)
- 6-K Current report (foreign issuer)
- 6-K Current report (foreign issuer)
- 6-K Current report (foreign issuer)
- 6-K Current report (foreign issuer)
Ownership 69
- 4 Levy Elliott M.: Change in insider ownership
- 4 Change in insider ownership
- 4 Change in insider ownership
- 3 Initial statement of insider ownership
- 3 Initial statement of insider ownership
- 3 Initial statement of insider ownership
- 3 Initial statement of insider ownership
- SCHEDULE 13D Major shareholder report
- 3 Initial statement of insider ownership
- 3 Initial statement of insider ownership
Prospectus 17
- S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
- 424B4 Prospectus filed pursuant to Rule 424(b)(4)
- DRSLTR Correspondence Related to Draft Registration Statement
- DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
- S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Other 50
- F-6 POS Post-effective amendment to a F-6EF registration
- EFFECT Notice of Effectiveness
- CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
- F-3/A Registration statement for specified transactions by certain foreign private issuers
- UPLOAD Letter (PDF)
- EFFECT Notice of Effectiveness
- EFFECT Notice of Effectiveness
- CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
- CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
- F-1/A Registration statement for securities of certain foreign private issuers